Your browser doesn't support javascript.
Ozone therapy for patients with SARS-COV-2 pneumonia: a single-center prospective cohort study
ALBERTO HERNANDEZ; MONTSERRAT VINALS; ASUNCION PABLOS; FRANCISCO VILAS; PETER J PAPADAKOS; DUMINDA N WIJEYSUNDERA; SERGIO BERGESE; MARC VIVES.
  • ALBERTO HERNANDEZ; Policlinica Ibiza Hospital
  • MONTSERRAT VINALS; Policlinica Ibiza Hospital
  • ASUNCION PABLOS; Policlinica Ibiza Hospital
  • FRANCISCO VILAS; Policlinica Ibiza Hospital
  • PETER J PAPADAKOS; University of Rochester, NY
  • DUMINDA N WIJEYSUNDERA; Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto
  • SERGIO BERGESE; Stony Brook University, New York, USA
  • MARC VIVES; Hospital Universitari Dr. J Trueta de Girona
Preprint in English | medRxiv | ID: ppmedrxiv-20117994
ABSTRACT
BackgroundThere is still no specific treatment strategies for COVID-19 other than supportive management. The potential biological benefits of ozonated autohemotherapy include reduced tissue hypoxia, decreased hypercoagulability, modulated immune function with inhibition of inflammatory mediators, improved phagocytic function, and impaired viral replication. ObjectiveTo determine the impact of the use of ozonated blood on time to clinical improvement in patients with severe COVID-19 pneumonia. DesignA Quasi-Randomized Controlled Trial determined by admittance to the hospital based on bed availability. SettingInternal Medicine ward at Policlinica Ibiza Hospital, Spain. ParticipantsEighteen patients with COVID-19 infection (laboratory confirmed) severe pneumonia admitted to hospital between 20th March and 19th April 2020. The mean age of the cohort was 68 years-old and 72% (n=13) were male. InterventionPatients admitted to the hospital during the study period were pre-randomized to different beds based on bed availability. Depending on the bed the patient was admitted, the treatment was ozone autohemotherapy or standard treatment. Patients in the therapy arm received ozonated blood twice daily starting on the day of admission for a median of four days. Each treatment involved administration of 200 mL autologous whole blood enriched with 200 mL of oxygen-ozone mixture with a 40 g/mL ozone concentration. Main OutcomesThe primary outcome was time from hospital admission to clinical improvement, which was defined as either hospital discharge or a two-point improvement in clinical status measured on a six-point ordinal scale. Secondary outcomes were clinical improvement measured on the 7th, 14th and 28th day after admission, as well as time to a two-fold reduction in concentrations of C-reactive protein, ferritin, D-dimer and lactate dehydrogenase. ResultsNine patients (50%) received ozonated autohemotherapy beginning on the day of admission. Ozonated autohemotherapy was associated with shorter time to clinical improvement (median [IQR]), 7 days [6-10] vs 28 days [8-31], p=0.04) and better outcomes at 14-days (88.8% vs 33.3%, p=0.01). In risk-adjusted analyses, ozonated autohemotherapy was associated with a shorter mean time to clinical improvement (-11.3 days, p=0.04, 95% CI -22.25 to -0.42). ConclusionOzonated autohemotherapy was associated with a significantly shorter time to clinical improvement in this quasi-randomized controlled trial. Given the small sample size and study design, these results require evaluation in larger randomized controlled trials.
Full text: Available Collection: Preprints Database: medRxiv Document Type: Preprint Language: English Year: 2020

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: medRxiv Document Type: Preprint Language: English Year: 2020
...